prediction
From 4Q onward, price increase effects, overseas coverage expansion, and securing bio cost competitiveness through collaboration with ADM are expected.
A prediction by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.
4분기 이후 판가 인상 효과와 해외 커버리지 확장, 그리고 ADM과의 협업을 통한 바이오 원가 경쟁력 확보가 기대됩니다.
Discussion
Related claims
라이신 P/Q is expected to grow together following the effectuation of 중국 반덤핑 관세, and the establishment of ADM과의 합작법인 is expected to secure cost competitiveness.report author · predictionSince the Q3 2026 earnings announcements, 2027 operating profit forecasts for domestic memory companies have been raised again after about four months of stagnation, driven by better-than-expected DRAM prices.하나증권 · statement3분기 실적은 컨센서스를 하회했으나, 4분기 벤틀리 및 아이브 콜라보 등을 통해 회복이 예상된다.리포트 작성자(증권사) · predictionCoverage initiated with a target price of 80,000 won, expecting MG and GD clinical results in 2027.하나증권 제약/바이오 김선아 · commitmentApple forecast that its fourth-quarter gross margin will be 45-46%, down from 47.9% in the third quarter, due to rising memory prices.FICC리서치부 전략/시황: 이경민 · prediction2027년에는 유가 Peak-out과 원화 강세에 따른 비용 절감 및 아웃바운드 수요 회복이 동시에 나타날 전망이다.하나증권 안도현 · prediction